safety tolerability

Related by string. Safety Tolerability * SAFETY . safetys . Safety . Safety : Civil Aviation Safety . Hazardous Materials Safety . Consumer Product Safety . safety Darren Sharper / Tolerability : safety tolerability pharmacokinetics . efficacy tolerability . favorable tolerability . tolerability pharmacokinetics * safety tolerability pharmacokinetic . safety tolerability pharmacodynamics *

Related by context. Frequent words. (Click for all words.) 73 tolerability 72 pharmacokinetics 68 pharmacokinetic profile 67 pharmacodynamics 66 pharmacokinetic 66 Phase Ib 65 dose escalation study 65 pharmacodynamic 64 double blind placebo 64 Phase IIa clinical 64 blind placebo controlled 63 Phase 2a clinical 63 Phase IIa 63 Phase 1b 62 placebo controlled 62 immunogenicity 62 Phase IIa trial 61 randomized placebo controlled 61 Phase 2b study 60 blind randomized placebo 60 randomized double 58 Phase IIb 58 efficacy 58 Phase 2b trial 58 Phase IIb clinical 58 Phase 2a 58 antiviral activity 58 dosing regimens 58 tolerability profile 57 antitumor activity 57 Phase 2b 57 Phase 2b clinical 57 Phase III clinical 57 Phase IIb trial 56 RG# [001] 56 LEVADEX 55 dose escalation 55 randomized controlled 55 randomized clinical 55 RDEA# 55 blind randomized 55 pivotal Phase 55 pivotal Phase III 55 preclinical studies 54 randomized 54 dose regimen 54 CYT# 54 mg dose 54 prospective randomized 54 investigational compound 54 eculizumab 54 randomized Phase 53 multicenter 53 carboplatin 53 IMGN# 53 orally administered 53 primary endpoint 53 clinical trial 52 evaluable patients 52 PRX # 52 investigational drug 52 monotherapy 52 bioavailability 52 CK # 52 administered orally 52 INCB# [002] 52 oral formulation 52 ANA# 51 ofatumumab 51 non inferiority 51 ARRY 51 MGCD# [002] 51 docetaxel 51 cutaneous T cell 51 secondary endpoints 50 preclinical 50 evaluable 50 primary efficacy endpoint 50 bavituximab 50 preclinical models 50 AP# [003] 50 Phase III 50 initiate Phase 50 Phase III clinical trials 50 bevirimat 50 Phase II 50 plasma concentrations 50 prospective cohort 50 CRx 50 gemcitabine 49 secondary endpoint 49 oral dosing 49 dosing regimen 49 voreloxin 49 hematologic malignancies 49 Preclinical studies 49 mg doses 49 XL# [003] 49 randomized controlled trial 49 mg/m2 49 HspE7

Back to home page